Physician profile
Manish Relan
NPI 1578539995
$180,635.31
in general payments reported to CMS, 2019-2025
36 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $32K · 2022: $46K · 2023: $26K · 2024: $22K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Honoraria: $15K · Food and Beverage: $12K · Travel and Lodging: $5,760 · Consulting Fee: $1,235 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,125.00 |
| Honoraria | $15,075.00 |
| Food and Beverage | $11,839.91 |
| Travel and Lodging | $5,760.20 |
| Consulting Fee | $1,235.00 |
| Education | $373.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $68,921.11 | 2019-2023 | Krystexxa |
| Abbvie INC. | $49,844.25 | 2019-2025 | |
| Amgen INC. | $46,483.50 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Janssen Biotech, INC. | $3,894.58 | 2019-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $1,755.74 | 2021-2025 | Saphnelo |
| Ucb, INC. | $1,489.83 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,251.94 | 2019-2025 | |
| Pfizer INC. | $1,037.99 | 2019-2025 | |
| Glaxosmithkline, LLC. | $749.16 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $735.59 | 2019-2025 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $645.26 | 2019-2025 | Orencia |
| Johnson & Johnson Health Care Systems INC. | $633.54 | 2019-2022 | |
| Lilly USA, LLC | $586.37 | 2020-2025 | Taltz, Zepbound |
| Genzyme Corporation | $496.21 | 2019-2024 | |
| Aurinia Pharma U.S., INC. | $441.85 | 2021-2025 | Lupkynis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $243.83 | 2019-2025 | Actemra, Gazyva |
| Radius Health, INC. | $183.41 | 2020-2025 | |
| Kyowa Kirin, INC. | $147.46 | 2024 | Crysvita |
| Sobi, INC | $145.22 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $142.62 | 2024-2025 | Purified Cortrophin Gel |
| Genentech, INC. | $112.61 | 2021 | |
| Alexion Pharmaceuticals, INC. | $111.89 | 2023-2025 | Strensiq |
| Sanofi-Aventis U.S. LLC | $99.00 | 2019 | |
| Edwards Lifesciences Corporation | $83.84 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Argenx US, INC. | $72.89 | 2024 | Vyvgart Hytrulo |
| Mallinckrodt Enterprises LLC | $69.47 | 2019 | |
| Janssen Scientific Affairs, LLC | $60.00 | 2024 | |
| Hikma Pharmaceuticals USA | $42.21 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $32.65 | 2022-2025 | Acthar |
| Celgene Corporation | $22.07 | 2019 | |
| Scilex Pharmaceuticals INC. | $21.53 | 2024 | |
| Fresenius Kabi USA, LLC | $21.29 | 2025 | |
| Sanofi US Services INC. | $18.08 | 2023 | |
| Eyevance Pharmaceuticals LLC | $13.78 | 2021 | |
| Sandoz INC. | $13.44 | 2023 | Hyrimoz |
| Medexus Pharma, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Relan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.